Clinical trial

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-04-01

PhasePHASE2

Study timeline

Study start (actual)2016-04-01Date precision: month

Registry last updated2020-01-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV-1 Infectionunresolved

Interventions

Visbiome Extra StrengthDRUG

PlaceboDRUG

Sponsors & collaborators

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infectionslead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Exegi Pharma, LLCcollaborator

Mapped research locations

New YorkNew York, United States3 ChicagoIllinois, United States2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 St LouisMissouri, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 SeattleWashington, United States1 ClevelandOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02706717 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.